Team publications 2021
1. CARVALHO-SCHNEIDER C, LAURENT E, LEMAIGNEN A, BEAUFILS E, BOURBAO-TOURNOIS C, LARIBI S, FLAMENT T, FERREIRA-MALDENT N, BRUYÈRE F, STEFIC K, GAUDY-GRAFFIN C, GRAMMATICO-GUILLON L, BERNARD L. Follow-up of adults with non-critical COVID-19 two months after symptoms' onset. Clin Microbiol Infect 2021 ; 27: 258-263.
2. DIALLO MS, SAMRI A, CHARPENTIER C, BERTINE M, CHEYNIER R, THIEBAUT R, MATHERON S, COLLIN F, BRAIBANT M, CANDOTTI D, BRUN-VÉZINET F, AUTRAN B. A comparison of cell activation, exhaustion and expression of HIV co-receptors and restriction factors in HIV-1 and HIV-2 infected Non Progressors. AIDS Res Hum Retroviruses 2021 ; 37, 214-223.
3. DROUIN A, MIGRAINE J, DURAND M-A, MOREAU A, GAILLARD J BERETTA M, ROINGEARD P, BOUVIN-PLEY M, BRAIBANT M. Escape of HIV-1 envelope glycoprotein from restriction of infection by IFITM3. J Virol 2021 ; 95, e01994-20.
4. EYMIEUX S, ROUILLÉ, Y, TERRIER O, SERON K, BLANCHARD E, ROSA-CALATRAVA M, DUBUISSON J, BELOUZARD S, ROINGEARD P. Ultrastructural modifications induced by SARS-CoV-2 in Vero cells : a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. Cell Molec Life Sci 2021; 78: 3565-3576.
5. BAL A, DESTRAS G, GAYMARD A, STEFIC K, MARLET J, EYMIEUX S, REGUE H, SEMANAS Q, D'AUBAREDE C, BILLAUD G, LAURENT F, GONZALEZ C, MEKKI Y, VALETTE M, BOUSCAMBERT M, GAUDY-GRAFFIN C, LINA B, MORFIN F, JOSSET L. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020. Euro Surveill 2021; 26, 2100008.
6. COCHARD J, BULL-MAURER A, TAUBER C, BURLAUD-GAILLARD J, MAZURIER F, MEUNIER JC, ROINGEARD P, CHOUTEAU P. Differentiated cells in prolonged hypoxia produce highly infectious native-like hepatitis C virus particles. Hepatology 2021; 74, 627-640.
7. NÉANT N, LINGAS G, LE HINGRAT Q, GHOSN J, ENGELMANN I, LEPILLER Q, GAYMARD A, FERRÉ V, HARTARD C, PLANTIER JC, THIBAULT V, MARLET J, MONTES B, BOUILLER K, LESCURE FX, TIMSIT JF, FAURE E, POISSY J, CHIDIAC C, RAFFI F, KIMMOUN A, ETIENNE M, RICHARD JC, TATTEVIN P, GAROT D, LE MOING V, BACHELET D, TARDIVON C, DUVAL X, YAZDANPANAH Y, MENTRÉ F, LAOUÉNAN C, VISSEAUX B, GUEDJ J. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci USA 2021, ;118(8):e2017962118.
8. MARIAGGI AA, GARDIENNET E, STEFIC K, ESSAT A, CHERET A, GOUJARD C, MEYER L, BARIN F, AVETTAND-FENOEL V. Immunoblots may not be effective in confirming the recency of HIV-1 infection. J Virol Methods 2021, 290:114074.
9. EYMIEUX S, BLANCHARD E, UZBEKOV R, HOURIOUX C, ROINGEARD P. Annulate lamellae and intracellular pathogens. Cell Microbiol 2021 ; 23, e13328.
10. ABUDUAINI T, ROY V, MARLET J, GAUDY-GRAFFIN C, BRAND D, BARONTI C, TOURET F, COUTARD B, MCBRAYER T, SCHINAZI R, AGROFOGLIO L. Synthesis and antiviral evaluation of (1,4-disubstituted-1,2,3-triazol)-(E)-2-methyl-but-2-enyl nucleoside phosphonate prodrugs. Molecules 2021; 26, e1493.
11. CAPPY P, CHAILLON A, PILLONEL J, ESSAT A, CHAIX ML, MEYER L, BARIN F, TIBERGHIEN P, LAPERCHE S. HIV transmission network analysis allows identifying unreported risk factors in HIV-positive blood donors in France. Transfusion 2021; 61, 1191-1201.
12. MARIAGGI AA, GARDIENNET E, STEFIC K, ESSAT A, CHERET A, GOUJARD C, MEYER L, BARIN F, AVETTAND-FENOEL V. Immunoblots may not be effective in confirming the recency of HIV-1 infection. J Virol Methods 2021; 114074.
13. HARB J, MENNESSON N, LEPETIT C, FOURNY M, LOUVOIS M, BOSSEBOEUF A, ALLAIN-MAILLET S, DECAUX O, MOREAU C, TALLET A, PIVER E, MOREAU P, SALLE V, BIGOT-CORBEL E, HERMOUET S. Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens. Cells 2021 ;10:438.
14. GUILLON A, LAURENT E, GODILLON L, KIMMOUN A, GRAMMATICO-GUILLON L. Long-term mortality of elderly patients after intensive care unit admission for COVID-19. Intensive Care Med 2021; in press
15. PLANAS D, BRUEL T, GRZELAK L, GUIVEL-BENHASSINE F, STAROPOLI I, PORROT F, PLANCHAIS C, BUCHRIESER J, RAJAH MM, BISHOP E, ALBERT M, DONATI F, PROT M, BEHILLIL S, ENOUF V, MAQUART M, SMATI-LAFARGE M, VARON E, SCHORTGEN F, YAHYAOUI L, GONZALEZ M, DE SÈZE J, PÉRÉ H, VEYER D, SÈVE A, SIMON-LORIÈRE E, FAFI-KREMER S, STEFIC K, MOUQUET H, HOCQUELOUX L, VAN DER WERF S, PRAZUCK T, SCHWARTZ O. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 2021; 27: 917-924.
16. DUJARDIN A, DE LA BLANCHARDIERE A, DINA J, STEFIC K, RAVEL C, BONHOMME J, VERDON R, FOURNIER AL. Leishmania and HIV co-diagnosis: how to understand medical history ? Front Immunol 2021; 12:669723.
17. INAMDAR K, TSAI F-C, DISBY R, DE PORET A, MANZI J, MERIDA P, MULLER R, LAPPALAINEN P, ROINGEARD P,MAK J, BASSEREAU P, FAVARD C, MURIAUX D. Full assembly of HIV-1 particles requires assistance of the membrane curvature factor IRSp53. eLife 2021; 10: e67321.
18. MARCELIN AG, CHARPENTIER C, BELLECAVE P, ABDI B, CHAIX ML, FERRE V, RAYMOND S, FOFANA D, BOCKET L, MIRAND A, LE GUILLOU-GUILLEMETTE H, MONTES B, AMIEL C, PALLIER C, FAFI-KREMER S, DE MONTE A, ALESSANDRI-GRADT E, SCHOLTES C, MAILLARD A, JEULIN H, BOUVIER-ALIAS M, ROUSSEL C, DOS SANTOS G, SIGNORI-SCHMUCK A, DINA J, VALLET S, STEFIC K, SOULIE C, CALVEZ V, DESCAMPS D, FLANDRE P; ANRS-MIE AC43 GROUP. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. J Antimicrob Chemother 2021; in press
19. MARLET J, LIER C, ROCH E, MOREAU A, COMBE B, HANDALA L, LEFEUVRE S, MAUGEY M, ELKRIEF L , D'ALTEROCHE L, POTIER P, BRAND D, GAUDY-GRAFFIN C. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure. Antiviral Res 2021;192:105106.
20. TASSI MF, LAURENT E, GRAS G, LOT F, BARIN F, DE GAGE SB, STEFIC K, GRAMMATICO-GUILLON L. PrEP monitoring and HIV incidence after PrEP initiation in France: 2016-18 nationwide cohort study. J Antimicrob Chemother 2021 ; in press
21. EYMIEUX S, UZBEKOV R, ROUILLÉ, Y, BLANCHARD E, HOURIOUX C, DUBUISSON J, BELOUZARD S, ROINGEARD P. Secretion vesicles are the principal means of SARS-CoV-2 egress. Cells 2021 ; 10:2047.
22. CAVAL V, SUSPÈNE R, KHALFI P, GAILLARD J, CAIGNARD G, VITOUR D, ROINGEARD P, VARTANIAN JP, WAIN-HOBSON S. Frame-shifted APOBEC3A encodes two alternative pro-apoptotic proteins that target the mitochondrial network. J Biol Chem 2021 ; 297: 101081.
23. GUILLON A, LAURENT E, DUCLOS A, GODILLON L, DEQUIN PF, AGRINIER N, KIMMOUN A, GRAMMATICO-GUILLON L. Case fatality inequalities of critically ill COVID-19 patients according to patient-, hospital- and region-related factors: a French nationwide study. Ann Intensive Care 2021, 11:127.
2. DIALLO MS, SAMRI A, CHARPENTIER C, BERTINE M, CHEYNIER R, THIEBAUT R, MATHERON S, COLLIN F, BRAIBANT M, CANDOTTI D, BRUN-VÉZINET F, AUTRAN B. A comparison of cell activation, exhaustion and expression of HIV co-receptors and restriction factors in HIV-1 and HIV-2 infected Non Progressors. AIDS Res Hum Retroviruses 2021 ; 37, 214-223.
3. DROUIN A, MIGRAINE J, DURAND M-A, MOREAU A, GAILLARD J BERETTA M, ROINGEARD P, BOUVIN-PLEY M, BRAIBANT M. Escape of HIV-1 envelope glycoprotein from restriction of infection by IFITM3. J Virol 2021 ; 95, e01994-20.
4. EYMIEUX S, ROUILLÉ, Y, TERRIER O, SERON K, BLANCHARD E, ROSA-CALATRAVA M, DUBUISSON J, BELOUZARD S, ROINGEARD P. Ultrastructural modifications induced by SARS-CoV-2 in Vero cells : a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release. Cell Molec Life Sci 2021; 78: 3565-3576.
5. BAL A, DESTRAS G, GAYMARD A, STEFIC K, MARLET J, EYMIEUX S, REGUE H, SEMANAS Q, D'AUBAREDE C, BILLAUD G, LAURENT F, GONZALEZ C, MEKKI Y, VALETTE M, BOUSCAMBERT M, GAUDY-GRAFFIN C, LINA B, MORFIN F, JOSSET L. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020. Euro Surveill 2021; 26, 2100008.
6. COCHARD J, BULL-MAURER A, TAUBER C, BURLAUD-GAILLARD J, MAZURIER F, MEUNIER JC, ROINGEARD P, CHOUTEAU P. Differentiated cells in prolonged hypoxia produce highly infectious native-like hepatitis C virus particles. Hepatology 2021; 74, 627-640.
7. NÉANT N, LINGAS G, LE HINGRAT Q, GHOSN J, ENGELMANN I, LEPILLER Q, GAYMARD A, FERRÉ V, HARTARD C, PLANTIER JC, THIBAULT V, MARLET J, MONTES B, BOUILLER K, LESCURE FX, TIMSIT JF, FAURE E, POISSY J, CHIDIAC C, RAFFI F, KIMMOUN A, ETIENNE M, RICHARD JC, TATTEVIN P, GAROT D, LE MOING V, BACHELET D, TARDIVON C, DUVAL X, YAZDANPANAH Y, MENTRÉ F, LAOUÉNAN C, VISSEAUX B, GUEDJ J. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci USA 2021, ;118(8):e2017962118.
8. MARIAGGI AA, GARDIENNET E, STEFIC K, ESSAT A, CHERET A, GOUJARD C, MEYER L, BARIN F, AVETTAND-FENOEL V. Immunoblots may not be effective in confirming the recency of HIV-1 infection. J Virol Methods 2021, 290:114074.
9. EYMIEUX S, BLANCHARD E, UZBEKOV R, HOURIOUX C, ROINGEARD P. Annulate lamellae and intracellular pathogens. Cell Microbiol 2021 ; 23, e13328.
10. ABUDUAINI T, ROY V, MARLET J, GAUDY-GRAFFIN C, BRAND D, BARONTI C, TOURET F, COUTARD B, MCBRAYER T, SCHINAZI R, AGROFOGLIO L. Synthesis and antiviral evaluation of (1,4-disubstituted-1,2,3-triazol)-(E)-2-methyl-but-2-enyl nucleoside phosphonate prodrugs. Molecules 2021; 26, e1493.
11. CAPPY P, CHAILLON A, PILLONEL J, ESSAT A, CHAIX ML, MEYER L, BARIN F, TIBERGHIEN P, LAPERCHE S. HIV transmission network analysis allows identifying unreported risk factors in HIV-positive blood donors in France. Transfusion 2021; 61, 1191-1201.
12. MARIAGGI AA, GARDIENNET E, STEFIC K, ESSAT A, CHERET A, GOUJARD C, MEYER L, BARIN F, AVETTAND-FENOEL V. Immunoblots may not be effective in confirming the recency of HIV-1 infection. J Virol Methods 2021; 114074.
13. HARB J, MENNESSON N, LEPETIT C, FOURNY M, LOUVOIS M, BOSSEBOEUF A, ALLAIN-MAILLET S, DECAUX O, MOREAU C, TALLET A, PIVER E, MOREAU P, SALLE V, BIGOT-CORBEL E, HERMOUET S. Comparison of Monoclonal Gammopathies Linked to Poliovirus or Coxsackievirus vs. Other Infectious Pathogens. Cells 2021 ;10:438.
14. GUILLON A, LAURENT E, GODILLON L, KIMMOUN A, GRAMMATICO-GUILLON L. Long-term mortality of elderly patients after intensive care unit admission for COVID-19. Intensive Care Med 2021; in press
15. PLANAS D, BRUEL T, GRZELAK L, GUIVEL-BENHASSINE F, STAROPOLI I, PORROT F, PLANCHAIS C, BUCHRIESER J, RAJAH MM, BISHOP E, ALBERT M, DONATI F, PROT M, BEHILLIL S, ENOUF V, MAQUART M, SMATI-LAFARGE M, VARON E, SCHORTGEN F, YAHYAOUI L, GONZALEZ M, DE SÈZE J, PÉRÉ H, VEYER D, SÈVE A, SIMON-LORIÈRE E, FAFI-KREMER S, STEFIC K, MOUQUET H, HOCQUELOUX L, VAN DER WERF S, PRAZUCK T, SCHWARTZ O. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med 2021; 27: 917-924.
16. DUJARDIN A, DE LA BLANCHARDIERE A, DINA J, STEFIC K, RAVEL C, BONHOMME J, VERDON R, FOURNIER AL. Leishmania and HIV co-diagnosis: how to understand medical history ? Front Immunol 2021; 12:669723.
17. INAMDAR K, TSAI F-C, DISBY R, DE PORET A, MANZI J, MERIDA P, MULLER R, LAPPALAINEN P, ROINGEARD P,MAK J, BASSEREAU P, FAVARD C, MURIAUX D. Full assembly of HIV-1 particles requires assistance of the membrane curvature factor IRSp53. eLife 2021; 10: e67321.
18. MARCELIN AG, CHARPENTIER C, BELLECAVE P, ABDI B, CHAIX ML, FERRE V, RAYMOND S, FOFANA D, BOCKET L, MIRAND A, LE GUILLOU-GUILLEMETTE H, MONTES B, AMIEL C, PALLIER C, FAFI-KREMER S, DE MONTE A, ALESSANDRI-GRADT E, SCHOLTES C, MAILLARD A, JEULIN H, BOUVIER-ALIAS M, ROUSSEL C, DOS SANTOS G, SIGNORI-SCHMUCK A, DINA J, VALLET S, STEFIC K, SOULIE C, CALVEZ V, DESCAMPS D, FLANDRE P; ANRS-MIE AC43 GROUP. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey. J Antimicrob Chemother 2021; in press
19. MARLET J, LIER C, ROCH E, MOREAU A, COMBE B, HANDALA L, LEFEUVRE S, MAUGEY M, ELKRIEF L , D'ALTEROCHE L, POTIER P, BRAND D, GAUDY-GRAFFIN C. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure. Antiviral Res 2021;192:105106.
20. TASSI MF, LAURENT E, GRAS G, LOT F, BARIN F, DE GAGE SB, STEFIC K, GRAMMATICO-GUILLON L. PrEP monitoring and HIV incidence after PrEP initiation in France: 2016-18 nationwide cohort study. J Antimicrob Chemother 2021 ; in press
21. EYMIEUX S, UZBEKOV R, ROUILLÉ, Y, BLANCHARD E, HOURIOUX C, DUBUISSON J, BELOUZARD S, ROINGEARD P. Secretion vesicles are the principal means of SARS-CoV-2 egress. Cells 2021 ; 10:2047.
22. CAVAL V, SUSPÈNE R, KHALFI P, GAILLARD J, CAIGNARD G, VITOUR D, ROINGEARD P, VARTANIAN JP, WAIN-HOBSON S. Frame-shifted APOBEC3A encodes two alternative pro-apoptotic proteins that target the mitochondrial network. J Biol Chem 2021 ; 297: 101081.
23. GUILLON A, LAURENT E, DUCLOS A, GODILLON L, DEQUIN PF, AGRINIER N, KIMMOUN A, GRAMMATICO-GUILLON L. Case fatality inequalities of critically ill COVID-19 patients according to patient-, hospital- and region-related factors: a French nationwide study. Ann Intensive Care 2021, 11:127.
Contact
Inserm - U1259 MAVIVHe
10 boulevard Tonnellé - BP 3223
37032 Tours Cedex 1 - France
Tél. : 33 (2) 47 36 61 27
Fax : 33 (2) 47 36 61 26
Deputy Administrator
Head : Fabrizio Mammano
Deputy Head : Denys Brand
Deputy Head : Hugues de Rocquigny